Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: [Problem] Provided are a production method for a multi-input/multi-output-type genetic switch or a transcription factor, and a multi-input/multi-output-type genetic switch or a transcription factor. [Solving Means] The inventors of the present invention have completed a production method for a multi-input/multi-output-type genetic switch or a transcription factor, essentially including the steps of “fusing two or more transcription factor genes to each other” and “introducing mutations into the fusion-type transcription factor gene,” and have further succeeded in obtaining a multi-input/multi-output-type genetic switch or a transcription factor by the method.

Abstract: A layer configuration prediction method is provided and includes: a specimen production step of producing multiple specimens by depositing layers of a material in configurations different from each other; a specimen measurement step of performing, on each specimen, measurement to acquire a texture parameter corresponding to a texture; a learning step of causing a computer to perform machine learning of a relation between each of the specimens and the texture parameter; a setting parameter calculation step of calculating a setting parameter corresponding to the texture set to a computer graphics image; and a layer configuration acquisition step of providing the setting parameter as an input to the computer having been caused to perform the machine learning, and acquiring an output representing the layering pattern of layers of the material corresponding to the setting parameter.

Abstract: The purpose of the present invention is to provide a medicament which is useful for prevention or treatment of muscle injury. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to a preventing or therapeutic agent for muscle injury containing the extract as an active ingredient. The preventing or therapeutic agent for muscle injury of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe medicament.

Abstract: Provided is a method for derivatizing an s-cis-diene compound with a Cookson-type derivatization reagent, the method including adding, in a reaction stopping step of stopping a derivatization reaction of the s-cis-diene compound, a decomposition inhibitor to inhibit decomposition of a derivative to be obtained.

Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.

Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.

Abstract: An object of the present invention is to provide a film which has a high visibility in a solid state and a product which has the film, with a simple material composition. One aspect of the present invention is a film which comprises a core-shell particle which has a core and a shell which covers the core. Moreover, another aspect of the present invention is a product which is covered with the film. Further, another aspect of the present invention is a solution in which core-shell particles are dispersed. The present invention makes it possible to provide a film which has a high visibility in a solid state and a product which has the film, with a simple material composition.

Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: The present invention relates to a guide RNA molecule that hybridizes with a target sequence containing a mutation site of a transforming growth factor ?-induced (TGFBI) gene associated with granular corneal degeneration.

Abstract: An image processing apparatus includes a processor including hardware. The processor is configured to: acquire video data; estimate a spatial distribution of a predetermined biological component for which a component spectrum temporally varies with respect to image data of a predetermined frame among a plurality of frames included in the video data; generate biological component video data in which the biological component is extracted from the video data based on the estimated spatial distribution of the biological component in the image data of the predetermined frame; and generate periodic variation video data of the biological component by applying, to the biological component video data, a filter for extracting a predetermined frequency component.

Abstract: A shaft torque control device executes highly responsive shaft-torque control even when spring rigidity of a connection shaft connecting an engine and dynamometer varies, and has a feedback control system including a nominal plant imitating input-output characteristics of a test system, generalized plant having nominal plant; controller providing an input with use of outputs and variation term causing variation in the nominal plant on the basis of a variation transfer function. In the controller, setting is made to satisfy a design condition. Nominal plant is structured with a two-inertia system configured by connecting two inertia bodies via a shaft having spring rigidity equal to a predetermined nominal value set to be a lower limit value in an assumed variation range of spring rigidity of the connection shaft. The variation transfer function is a positive real function. Spring rigidity in the nominal plant Na increases from the nominal value.

Abstract: Provided are novel polymer particles for carrying a physiologically active substance and a method of preparing the same. The polymer particles for carrying a physiologically active substance can provide an analytical reagent, which has high analytical precision and sensitivity and can be stably prepared; can easily and precisely control the amount of functional groups carrying the physiologically active substance; can introduce, onto the surface of latex particles, a hydrophilic compound for inhibiting a nonspecific reaction; and can be prepared to have a narrow and uniform particle size distribution.

Abstract: A seat with a ventilation system that maintains seated person's coolness by blowing air to minimum segments of a seatback and a seat cushion so that seated person's comfort is maintained is provided. Air-blowing means is controlled in air-blowing quantity and air-blowing time periodically by air-blowing control means, and air blowing in each period is set to include a first term T1 in which a predetermined quantity of air is blown and a second term T2 in which the predetermined quantity of air to be blown is gradually reduced.

Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: Shown is a method for producing a liquid crystal capsule having a particle diameter of 30 to 150 nanometers, and a method for producing a liquid crystal capsule without using a homogenizer. The disclosure concerns a method for producing a liquid crystal capsule, including a step of preparing an emulsion by performing phase inversion emulsification of a mixed material obtained by mixing a liquid crystal composition, a monomer, a surfactant, and a polymerization initiator; and a step of producing a liquid crystal capsule by applying a coacervation method to the emulsion. The disclosure also concerns a liquid crystal capsule having a liquid crystal composition, a surfactant and a capsule wall, wherein the capsule wall has a closed curved shape, the liquid crystal composition and a hydrophobic moiety of the surfactant are arranged inside the capsule wall, and a hydrophilic moiety of the surfactant is arranged outside the capsule wall.

Abstract: Methods of producing hepatocyte lineage cells are provided. The method can include transfecting a cell with one or more expression vectors. For example, a cell can be transfected with a first expression vector containing a first gene that encodes CCAAT/enhancer binding protein alpha (CEBPA), a second expression vector containing a second gene that encodes CCAAT/enhancer binding protein beta (CEBPB), a third expression vector containing a third gene that encodes forkhead box A1 (FOXA1), and a fourth expression vector containing a fourth gene that encodes forkhead box A3 (FOXA3). The method can include culturing the transfected cell obtained in a growth environment. The transfected cell can be cultured in Williams' E medium, ReproFF (feeder-free media maintaining pluripotency) medium, or both. Transfected and/or hepatocyte lineage cells obtained by a method of the present invention are also provided.

Abstract: Objects of the present invention are to find a marker by which progression of arteriosclerosis can be directly grasped, to thereby provide motivation for prevention or treatment of arteriosclerosis itself, and to provide means for accurately grasping condition of arteriosclerosis-related disease including arteriosclerotic disease. The invention provides a method for acquiring data on progression of arteriosclerosis, the method including determining a level of an antibody against SH3BP5 protein or a part thereof in a body fluid sample collected from a biological body, and a data acquisition kit for performing the data acquisition method.